182 related articles for article (PubMed ID: 10278618)
1. Preferred provider organizations and antitrust policy: some recent issues.
Costillo LB
Health Matrix; 1986; 4(2):22-5. PubMed ID: 10278618
[TBL] [Abstract][Full Text] [Related]
2. Preferred provider organizations, price-fixing and Section 1 of the Sherman Act.
Bluhm RJ
Health Matrix; 1987; 5(3):9-16. PubMed ID: 10285386
[TBL] [Abstract][Full Text] [Related]
3. Are PPOs a competitive force or antitrust risk?
Enders RJ
Healthc Financ Manage; 1986 May; 40(5):52-60. PubMed ID: 10276171
[TBL] [Abstract][Full Text] [Related]
4. The development of preferred provider organizations and its antitrust implications.
Maram BS
J Med Pract Manage; 1985 Oct; 1(2):130-5. PubMed ID: 10281825
[TBL] [Abstract][Full Text] [Related]
5. Perspectives. PPOs face antitrust problems.
Wash Rep Med Health; 1984 Nov; 38(44):suppl 4p. PubMed ID: 10268861
[No Abstract] [Full Text] [Related]
6. An assessment of the anticompetitive effects of preferred provider organizations.
Greaney TL; Sindelar JL
Inquiry; 1987; 24(4):384-91. PubMed ID: 2961699
[TBL] [Abstract][Full Text] [Related]
7. Monopolies, Maricopa, and marketing: a case study.
Perkins J; Mercer A; McClary C
Hosp Health Serv Adm; 1986; 31(4):34-44. PubMed ID: 10277339
[TBL] [Abstract][Full Text] [Related]
8. Court: Indiana Blues may adopt PPO plan without antitrust scrutiny.
Allen HS; Rothschild IS
Health Law Vigil; 1986 Apr; 9(8):4-5. PubMed ID: 10278389
[No Abstract] [Full Text] [Related]
9. Federal antitrust agencies send mixed signals to PPOs.
Enders RJ
Health Care Law Newsl; 1986 Jul; 1(1):12-4. PubMed ID: 10277502
[No Abstract] [Full Text] [Related]
10. Planning PPOs to minimize antitrust risk.
Clanton DA
Hospitals; 1985 Mar; 59(5):96, 98. PubMed ID: 3972373
[No Abstract] [Full Text] [Related]
11. Can provider antitrust suits against payers be successful?
Enders RJ
Healthc Financ Manage; 1986 Jun; 40(6):72-80. PubMed ID: 10276682
[TBL] [Abstract][Full Text] [Related]
12. Antitrust and the new competition in health care: excerpts.
Ginsburg DH
Med Prod Sales; 1986 Apr; 17(4):39-42. PubMed ID: 10276459
[No Abstract] [Full Text] [Related]
13. The FTC and provider-controlled PPO price negotiations.
Miles JJ
Health Law Vigil; 1988 Jan; 11(3):6-10. PubMed ID: 10285716
[No Abstract] [Full Text] [Related]
14. PPOs facing potential antitrust worries.
Tarnoff S
Bus Insur; 1985 Jul; 19(29):16, 20. PubMed ID: 10271746
[No Abstract] [Full Text] [Related]
15. Alternative delivery systems are focus of antitrust scrutiny.
Scammon DL; Fuller DA; Sheffet MJ
J Health Care Mark; 1987 Jun; 7(2):77-81. PubMed ID: 10282715
[No Abstract] [Full Text] [Related]
16. Pharmacy participation in PPOs: an antitrust review.
Health Matrix; 1984-1985 Winter; 2(4):35-7. PubMed ID: 10272758
[No Abstract] [Full Text] [Related]
17. Understanding antitrust: focus on the relevant market.
Enders RJ
Healthc Financ Manage; 1986 Feb; 40(2):25-32. PubMed ID: 10275004
[TBL] [Abstract][Full Text] [Related]
18. How can PPOs control prices without violating antitrust laws?
Fried JM
Hosp Prog; 1984 Mar; 65(3):34-7. PubMed ID: 10265221
[TBL] [Abstract][Full Text] [Related]
19. Evaluating antitrust risk in joint provider negotiations with payors.
Leonard EJ
Med Staff Couns; 1992; 6(1):41-7. PubMed ID: 10115450
[TBL] [Abstract][Full Text] [Related]
20. Proposed FTC consent order first to prohibit PPO price-fixing and concerted negotiations.
Miles JJ
Health Law Vigil; 1988 Jan; 11(2):9-10, 14. PubMed ID: 10285312
[No Abstract] [Full Text] [Related]
[Next] [New Search]
